When we forayed into the Life Sciences industry, we did it with an aim to transform how people are cured and help them live a better life. In less than six months, we have already become the leader in the segment with more than 8000 active customers worldwide.
This is also the time when the world has been grappling and jostling with an unprecedented global health crisis. Life Sciences companies and the broader healthcare ecosystem, from those working in research and clinical development, to manufacturing medical devices and patient care are at the forefront of the race to contain and fight this crisis. There has been a massive surge in demand for medicines and new drugs, vaccines, ventilators, PPE kits, personal medical devices, telehealth check-up and medical facilities.
At Dassault Systemes, we are enabling and empowering the Life Sciences and healthcare ecosystem with virtual design and engineering universes powered by our 3DEXPERIENCE platform. To showcase the effectivity and capabilities of our disruptive technology for Life Sciences, we conceptualized and organized The World After: From Things to Life, an event to bring CXOs, business leaders and decision makers from India’s thriving Life Sciences’ companies under one roof.
On 23rd June, 2020, more than 800 attendees from the life sciences industry in India joined the event through a rich and interactive digital interface that had experiential elements of a physical event. At this virtual congregation, industry experts of Dassault Systemes, shared insights about how digitalization and emerging technologies like Artificial Intelligence, Machine Learning, Data Analytics and Additive Manufacturing have led transformations in Pharma, Biotech, Medical Device manufacturing and Patient Care. Addressing the business challenges of the life sciences industry, Dassault Systèmes demonstrated the “License to Cure for Biopharma,” “ONE Lab,” and “Accelerated Device” industry solution experiences based on the 3DEXPERIENCE platform
Samson KHAOU, Executive Vice President, Asia Pacific, Dassault Systemes and Deepak NG, Managing Director, India, Dassault Systemes commenced the event with a captivating welcome note that encompassed the future roadmap of the company in Life Sciences and its aim to be the catalyst of technology led innovation in this industry. The note focused on the potential of Startups and SMEs to drive this innovation and the manifestation of Virtual Twin experience of human body for improved healthcare.
His Excellency Emmanuel LENAIN, Ambassador of France to India, who was one of the guest speakers at the event, spoke about the need for better collaboration between Government, civil societies, universities and the role of science to fight the current global crisis of the COVID-19 pandemic. He further iterated about the close partnership and synergy between the two countries, India and France, and mentioned about the French Government’s initiative to invest 200 million Euros in India through the Agence Française de Développement (AFD). The investment is aimed to improve the accessibility of basic healthcare services for the people of India.
Oure keynote guest speaker, Kiran MAZUMDAR-SHAW, Executive Chairperson, BIOCON, spoke about the challenges and opportunities for Indian pharmaceutical industry, in the post COVID-19 world. She asserted the capability of the industry to become a global hub by ramping up indigenous testing, developing ventilators and playing a pivotal role in getting Covid-19 vaccination to everyone in the world. Her detailed speech is capture here.
This was followed by a rich and engaging discussion between Claire BIOT, Vice President, Life Sciences, Dassault Systèmes and Renuka SRINIVASAN, Sales Operations Excellence Expert, SIMULIA, Dassault Systèmes, about the role and importance of Virtual Universes for Modeling and Simulation in the Life Sciences. They provided a brief overview about Dassault Systemes’ reach within the global Life Sciences and Healthcare industry, key investments and insights about market opportunity. They also showcased successful customer stories of IASO, GC Pharma and B. Braun.
Customers of Dassault Systemes from Life Sciences segment- IPCA, Skanray, Sahajanand Medical Technologies, Lupin, Agappe Diagnostics, Stryker, Brainsight, COMOFI Medtech, HCL Technologies and Jamia Milia Islamia University shared their knowledge and know-how.
The pharma segment of the event covered topics like digital continuity in the pharmaceutical industry, revolutionizing the drug development process with artificial intelligence, design and development of SARS-CoV-2 main protease inhibitors, optimizing laboratories and leveraging knowledge to improve time to market. Pharma and biopharma companies are moving towards unified platforms that help in drug research and discovery enhancing the ecosystem- research, development, manufacturing and quality and compliance. “Dassault Systèmes’ solution for quality control labs greatly reduced data input, transcription, and integrity validation efforts increased the overall productivity of the lab,” said Ashok Nayak, CIO, IPCA Laboratories.
The patient care segment in the event discussed “In-Silico in healthcare,” optimizing efficacy and safety for medical devices, simulation-driven new product development (NPD), simulation for understanding the functional dynamics of the brain and therapeutic stimulations using AI. The patient care sector is changing rapidly with a focus on improving patient outcomes and a shift from intermittent treatments to a continuous engagement driven by simulation technologies. “Multiphysics simulation capabilities have helped in the indigenous research and development of minimally invasive coronary stent systems as well as in maximizing their life and performance,” said Dr. Ramanan Lakshminarayanan, Chief Technology Officer, Sahajanand Medical Technologies.
The medical devices segment in the event highlighted faster time to market of innovative medical devices, and key technology solutions adopted in the diagnostics segment. Medical device manufacturers are moving away from point solutions for mechanical and electrical design, simulation, product data management (PDM) and technical communication, and toward integrated product development platforms to introduce product faster into the market and improve the overall performance and reliability, which is always the big challenge for them. “Medical Device manufacturers have to embrace digital technology to overcome the challenges in the manufacturing, product delivery, supply chain etc., which used to be an option in the past; now it is a must to sustain in the market and be innovative,” said Vishwaprasad Alva, Managing Director, Skanray.
The event featured dedicated break-out sessions with deep dive discussions about how Dassault Systemes’ 3DEXPERIENCE platform can redefine the three specific sub-segments in Life Sciences: Medical Devices; Pharmaceuticals and Biotechnology; Patient Care.
The World After: From Things to Life, is the first among many milestones for us, in our journey towards becoming a pioneer and leader in the Life Sciences industry. We believe that Dassault Systemes, can not only be the enabler but also a catalyst for the entire ecosystem and fuel diverse synergies with one common mission: Put innovation at the heart of everything to help people lead healthier lives.